Skip to main content
OpenTrials
Completed

NCT Number: NCT01797783

Clinical Evaluation of the Safety and Efficacy of a New Multifocal Contact Lens

The purpose of this study was to demonstrate substantial equivalence of the new DAILIES® AquaComfort Plus® Multifocal (DACP MF) contact lens to the commercially available Focus® DAILIES® Progressives (FDP) contact lens.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Sign Informed Consent Document.
  • Presbyopic and require a spectacle add of up to and including 3.00 diopters (D).
  • Currently wear soft contact lenses.
  • Willing and able to wear multifocal contact lenses in both eyes within the available range of powers for this trial and comply with the wearing and replacement schedule.
  • Manifest cylinder less than or equal to 1.00 D.
  • Able to achieve best corrected visual acuity (BCVA) of 20/25 or better (Snellen) in each eye at distance (as determined by manifest refraction).
  • Able to achieve distance visual acuity of 20/40 (Snellen) or better in each eye with study lenses and deem subjective vision as satisfactory at time of dispense.
  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

  • Any anterior segment infection, inflammation, disease, or abnormality that contraindicates contact lens wear within 6 months prior to enrollment.
  • Any use of systemic or ocular medications for which contact lens wear could be contraindicated.
  • History of corneal or refractive surgery.
  • Biomicroscopy findings greater than Grade 2 at baseline.
  • A pathologically dry eye that precludes contact lens wear.
  • Monocular (only one eye with functional vision).
  • Wear habitual contact lenses on an extended wear schedule (any number of nights of overnight wear on a regular basis).
  • History of intolerance or hypersensitivity to any component of the investigational products.
  • Concurrent participation in a contact lens or contact lens care product clinical trial or within the previous 30 days.
  • Eye injury or ocular or intra-ocular surgery within 6 months prior to enrollment.
  • Other protocol-defined exclusion criteria may apply.

Treatment and study plan

Nelfilcon A multifocal contact lens with comfort additive

Device

Nelfilcon A multifocal contact lens

Device

Primary outcomes

  1. Subjective Overall Vision

    Time frame: Up to Day 30

    The participant was instructed to, "Please rate the aggregate of distance, intermediate, and near vision quality. Fill in the circle below the number that indicates your selection. Rate eyes together, marking only 1 circle for both eyes. Higher numbers mean better vision." The response was recorded on a continuous scale from 1-10 (1=poor, 10=excellent).

Secondary outcomes

  1. Binocular Snellen Visual Acuity (VA) at Distance With Study Lenses

    Time frame: Up to Day 30

    Visual Acuity was tested while reading a chart at 20-foot equivalent distance from the participant with both eyes together. The Snellen fraction compares the participant's result to the result expected from the 'normal' visual system. The numerator represents the distance between the participant and the chart, and the denominator represents the distance at which a person with 'normal' vision would be able to discern the same letter size. 20/20 is considered to be 'normal' vision, whereas visual acuity of 20/40 means the participant is able to read a certain size letter 20 feet away that a person with 'normal' vision would be able to read from 40 feet away. A larger denominator, therefore, indicates a lower visual acuity.

  2. Binocular Snellen Visual Acuity (VA) at Near (40cm) With Study Lenses

    Time frame: Up to Day 30

    Visual Acuity was tested while reading charts at a distance of 40 cm from the participant with both eyes together. The Snellen fraction 20/20 represents 'normal' near vision. A larger denominator indicates a lower visual acuity.

Sponsors and collaborators

Lead sponsor

Alcon Research

Industry

Registry information

Important dates

Study start
2013
Primary completion
2013
Study completion
2013
First posted
Feb 25, 2013
Registry last updated
May 23, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.